The Effect of Disease-Modifying Drugs on Brain Atrophy in Relapsing-Remitting Multiple Sclerosis: A Meta-Analysis

Clinical Relevance of Brain Volume Measures in Multiple Sclerosis

(2014) Nicola De Stefano et al.   CNS DRUGS

New management algorithms in multiple sclerosis

(2014) Per Soelberg Sorensen   CURRENT OPINION IN NEUROLOGY

MRI measures should be a primary outcome endpoint in Phase III randomized, controlled trials in multiple sclerosis: Yes

(2014) Maria Pia Sormani et al.   Multiple Sclerosis Journal

Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

(2013) Maria Pia Sormani et al.   ANNALS OF NEUROLOGY

BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety

(2013) Robert J. Fox et al.   CURRENT MEDICAL RESEARCH AND OPINION

Neuroprotection with glatiramer acetate: evidence from the PreCISe trial

(2013) Douglas L. Arnold et al.   JOURNAL OF NEUROLOGY

Preventing brain atrophy should be the gold standard of effective therapy in MS (after the first year of treatment): Yes

(2013) Richard A Rudick et al.   Multiple Sclerosis Journal

Preventing brain atrophy should be the gold standard of effective therapy in multiple sclerosis (after the first year of treatment): Commentary

(2013) DL Arnold et al.   Multiple Sclerosis Journal

Preventing brain atrophy should be the gold standard of effective theraphy in MS (after the first year of treatment): No

(2013) M Filippi et al.   Multiple Sclerosis Journal

Early brain pseudoatrophy while on natalizumab therapy is due to white matter volume changes

(2013) Angela Vidal-Jordana et al.   Multiple Sclerosis Journal

The efficacy and safety of daclizumab and its potential role in the treatment of multiple sclerosis

(2013) Ron Milo   Therapeutic Advances in Neurological Disorders

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

(2012) Alasdair J Coles et al.   LANCET

Natalizumab strongly suppresses cortical pathology in relapsing–remitting multiple sclerosis

(2012) F Rinaldi et al.   Multiple Sclerosis Journal

Time to first relapse as an endpoint in multiple sclerosis clinical trials

(2012) MP Sormani et al.   Multiple Sclerosis Journal

Modeling MR Imaging Enhancing-Lesion Volumes in Multiple Sclerosis: Application in Clinical Trials

(2011) I.J. van den Elskamp et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

(2011) Chris H. Polman et al.   ANNALS OF NEUROLOGY

MRI predictors of cognitive outcome in early multiple sclerosis

(2011) M. S. A. Deloire et al.   NEUROLOGY

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity

(2010) Joanne L. Jones et al.   BRAIN

Therapy of MS

(2010) Reza Vosoughi et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Fingolimod is a potential novel therapy for multiple sclerosis

(2010) Orhan Aktas et al.   Nature Reviews Neurology

Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes

(2010) N. De Stefano et al.   NEUROLOGY

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mechanisms of neuronal dysfunction and degeneration in multiple sclerosis

(2010) Ranjan Dutta et al.   PROGRESS IN NEUROBIOLOGY

The relation between inflammation and neurodegeneration in multiple sclerosis brains

(2009) Josa M. Frischer et al.   BRAIN

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

(2009) Alessandro Liberati et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review

(2009) Blandine Grassiot et al.   JOURNAL OF NEUROLOGY